Literature DB >> 19863340

Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood.

Vladan Rajić1, Richard Aplenc, Marusa Debeljak, Veronika Velensek Prestor, Natasa Karas-Kuzelicki, Irena Mlinaric-Rascan, Janez Jazbec.   

Abstract

Anthracyclines have contributed significantly to the increased cure rate in pediatric oncology. Cardiac toxicity is an important late effect after anthracycline treatment and is thought to occur by reactive oxygen species mediated cardiac damage. We hypothesized that deactivating variants of superoxide dismutase II (SOD2) [rs4880 (-9Val > Ala)], catalase (CAT) [rs1001179 (-262C > T) and rs10836235 (c.66 + 78C > T)], GSTT1, and GSTM1 may increase the risk of developing cardiac toxicity, in patients exposed to anthracyclines. The hypothesis was tested in a cohort of 76 long-term survivals of acute lymphoblastic leukemia in childhood. Cardiac damage was evaluated as an attributive variable and compared to gene polymorphisms. In our study group, we show statistically significant correlation between CC homozygosity for CAT (rs10836235 (c.66 + 78C > T)) and cardiac damage after anthracycline exposure (p = 0.020). We found no statistically significant correlation between cardiac damage after anthracycline exposure and deactivating variants of SOD2 [rs4880 (-9Val > Ala)], CAT [rs1001179 (-262C > T), GSTT1, and GSTM1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19863340     DOI: 10.1080/10428190903177212

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  38 in total

1.  PharmGKB summary: very important pharmacogene information for GSTT1.

Authors:  Caroline F Thorn; Yuan Ji; Richard M Weinshilboum; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-08       Impact factor: 2.089

2.  Doxorubicin pathways: pharmacodynamics and adverse effects.

Authors:  Caroline F Thorn; Connie Oshiro; Sharon Marsh; Tina Hernandez-Boussard; Howard McLeod; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

3.  Pharmacogenomics meets precision cardio-oncology: is there synergistic potential?

Authors:  Jennifer K Hockings; Jessica A Castrillon; Feixiong Cheng
Journal:  Hum Mol Genet       Date:  2020-10-20       Impact factor: 6.150

Review 4.  Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity.

Authors:  Volker M Lauschke; Yitian Zhou; Magnus Ingelman-Sundberg
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

Review 5.  Frailty and aging in cancer survivors.

Authors:  Kirsten K Ness; Matthew D Wogksch
Journal:  Transl Res       Date:  2020-05-01       Impact factor: 7.012

6.  Induced Pluripotent Stem Cell-Derived Cardiomyocytes: A Platform for Testing For Drug Cardiotoxicity.

Authors:  Daniel Bernstein
Journal:  Prog Pediatr Cardiol       Date:  2017-07-18

Review 7.  Systems biology approaches to adverse drug effects: the example of cardio-oncology.

Authors:  Sherry-Ann Brown; Nicole Sandhu; Joerg Herrmann
Journal:  Nat Rev Clin Oncol       Date:  2015-10-13       Impact factor: 66.675

Review 8.  Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.

Authors:  Brian C Jensen; Howard L McLeod
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

Review 9.  Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity.

Authors:  Folefac Aminkeng; Colin J D Ross; Shahrad R Rassekh; Soomi Hwang; Michael J Rieder; Amit P Bhavsar; Anne Smith; Shubhayan Sanatani; Karen A Gelmon; Daniel Bernstein; Michael R Hayden; Ursula Amstutz; Bruce C Carleton
Journal:  Br J Clin Pharmacol       Date:  2016-06-30       Impact factor: 4.335

Review 10.  Cancer pharmacogenomics in children: research initiatives and progress to date.

Authors:  Shahrad Rod Rassekh; Colin J D Ross; Bruce C Carleton; Michael R Hayden
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.